A biochemical study found that a cytosolic binding protein could influence measured CYP3A4-mediated diazepam oxidation.
Investigators examined fatty-acid-binding protein 1, drug binding and reconstituted metabolic systems. FABP1 bound diazepam, and assay and kinetic-modeling results supported concentration-dependent effects on its oxidation. Adding cytosol to liver microsomes attenuated diazepam metabolism, while another tested substrate behaved differently.
These were laboratory systems and kinetic simulations, not treated volunteers. Protein concentrations, binding and assay composition affect measured intrinsic clearance. A preferred model of substrate transfer is not proof that a patient’s clearance changed by the same amount, and findings for one substrate cannot automatically be transferred to another.
For pharmacokinetic explanation, distinguish intrinsic enzyme activity from whole-body clearance. This source helps explain why microsomal and cellular estimates may disagree. It cannot establish a clinical interaction, dose adjustment or individual elimination half-life without relevant human exposure data and patient-specific context.
Source reviewed: Interaction of Cytochrome P450 3A4 with Fatty Acid Binding Protein 1 and Relevance to Drug Metabolis (PMC13036779). Forensic implications are interpretive analysis of the supplied paper.
Related reading: Acacetin Changed Diazepam and Metabolite Exposure in Rats.